Other
Proceeds From Interest Received
Royalty Pharma Proceeds From Interest Received increased by 1.9% to $6.50M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 46.0%, from $12.03M to $6.50M. Over 4 years (FY 2021 to FY 2025), Proceeds From Interest Received shows an upward trend with a 81.9% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
StatementCash Flow Statement
SectionOther
CategoryProfitability
SignalHigher is better
VolatilityModerate
First reportedQ1 2018
Last reportedQ1 2026May 6, 2026
How to read this metric
Higher interest received indicates a larger or higher-yielding asset base, driving core revenue.
Detailed definition
The total cash collected from interest-bearing assets, such as loans and investment securities. For a bank, this represe...
Peer comparison
Directly comparable across the banking sector as a measure of interest income generation.
Metric ID:
other_proceeds_from_interest_receivedHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $784.00K | $672.00K | $131.00K | $482.00K | $2.78M | $7.29M | $14.43M | $15.57M | $18.95M | $28.62M | $8.47M | $6.43M | $14.48M | $16.53M | $9.04M | $12.03M | $8.66M | $7.25M | $6.37M | $6.50M |
| QoQ Change | — | -14.3% | -80.5% | +267.9% | +476.8% | +162.4% | +97.8% | +7.9% | +21.7% | +51.1% | -70.4% | -24.1% | +125.3% | +14.1% | -45.4% | +33.1% | -28.0% | -16.3% | -12.1% | +1.9% |
| YoY Change | — | — | — | — | +254.6% | +985.4% | >999% | >999% | +581.5% | +292.4% | -41.3% | -58.7% | -23.5% | -42.2% | +6.7% | +87.0% | -40.2% | -56.2% | -29.5% | -46.0% |
Range$131.00K – $28.62M
CAGR+56.1%
Avg YoY Growth+994.5%
Median YoY Growth-8.4%
Proceeds From Interest Received at Other Companies
Frequently Asked Questions
- What is Royalty Pharma's proceeds from interest received?
- Royalty Pharma (RPRX) reported proceeds from interest received of $6.50M in Q1 2026.
- How has Royalty Pharma's proceeds from interest received changed year-over-year?
- Royalty Pharma's proceeds from interest received decreased by 46.0% year-over-year, from $12.03M to $6.50M.
- What is the long-term trend for Royalty Pharma's proceeds from interest received?
- Over 4 years (2021 to 2025), Royalty Pharma's proceeds from interest received has grown at a 81.9% compound annual growth rate (CAGR), from $3.14M to $34.31M.
- What does proceeds from interest received mean?
- Total cash received from interest on loans and investments.